125 related articles for article (PubMed ID: 17634823)
1. Polycythaemia vera and JAK2 mutation.
Mannucci PM
Intern Emerg Med; 2007 Jun; 2(2):147. PubMed ID: 17634823
[No Abstract] [Full Text] [Related]
2. An increase in diagnostic JAK2 V617F mutation testing: Is masked polycythaemia vera the explanantion?
Langabeer SE
Eur J Intern Med; 2018 Jun; 52():e37-e38. PubMed ID: 29622375
[No Abstract] [Full Text] [Related]
3. Prevalance of JAK2 V617F and exon 12 mutations in polycythaemia vera.
Scott LM; Beer PA; Bench AJ; Erber WN; Green AR
Br J Haematol; 2007 Nov; 139(3):511-2. PubMed ID: 17910642
[No Abstract] [Full Text] [Related]
4. [From gene to disease; JAK2 and polycythaemia vera].
Koene HR; Biemond BJ; van der Schoot CE
Ned Tijdschr Geneeskd; 2007 Aug; 151(32):1784-7. PubMed ID: 17822250
[TBL] [Abstract][Full Text] [Related]
5. Two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients.
Butcher CM; Hahn U; To LB; Gecz J; Wilkins EJ; Scott HS; Bardy PG; D'Andrea RJ
Leukemia; 2008 Apr; 22(4):870-3. PubMed ID: 17914411
[No Abstract] [Full Text] [Related]
6. Mutations in exon 12 of JAK2 are mainly found in JAK2 V617F-negative polycythaemia vera patients.
Kouroupi E; Zoi K; Parquet N; Zoi C; Kiladjian JJ; Grigoraki V; Vainchenker W; Lellouche F; Marzac C; Schlageter MH; Dosquet C; Scott LM; Fenaux P; Loukopoulos D; Chomienne C; Cassinat B
Br J Haematol; 2008 Aug; 142(4):676-9. PubMed ID: 18503583
[No Abstract] [Full Text] [Related]
7. Apparent 'JAK2-negative' polycythaemia vera due to compound mutations in exon 14.
Tiong IS; Casolari DA; Moore S; Nguyen T; Van Velzen MJM; Zantomio D; Scott HS; D'Andrea RJ; Hahn CN; Ross DM
Br J Haematol; 2017 Jul; 178(2):333-336. PubMed ID: 27136492
[No Abstract] [Full Text] [Related]
8. Existence of JAK2 mutation 19 years prior to the development of overt polycythemia vera.
Shimazu Y
Hematol Oncol; 2018 Feb; 36(1):355-356. PubMed ID: 28332734
[No Abstract] [Full Text] [Related]
9. JAK2 exon 12 mutation in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis: Not an exclusive mutation to polycythaemia vera.
Inano T; Araki M; Morishita S; Imai M; Yasuda H; Nitta H; Ito M; Edahiro Y; Ochiai T; Misawa K; Fukuda Y; Ohsaka A; Komatsu N
Br J Haematol; 2019 Oct; 187(1):e27-e31. PubMed ID: 31418453
[No Abstract] [Full Text] [Related]
10. The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera.
Olcaydu D; Skoda RC; Looser R; Li S; Cazzola M; Pietra D; Passamonti F; Lippert E; Carillo S; Girodon F; Vannucchi A; Reading NS; Prchal JT; Ay C; Pabinger I; Gisslinger H; Kralovics R
Leukemia; 2009 Oct; 23(10):1924-6. PubMed ID: 19440215
[No Abstract] [Full Text] [Related]
11. JAK2 mutations in polycythemia vera--molecular mechanisms and clinical applications.
Tefferi A
N Engl J Med; 2007 Feb; 356(5):444-5. PubMed ID: 17267904
[No Abstract] [Full Text] [Related]
12. Tumour lysis syndrome after splenic irradiation in a patient with JAK2 V617F post-polycythaemia vera myelofibrosis.
Jain S; Harrison C; McMullin MF; Houston RF
Clin Oncol (R Coll Radiol); 2010 Dec; 22(10):893. PubMed ID: 20692135
[No Abstract] [Full Text] [Related]
13. JAK2 exon 12 mutation in JAK2V617F-negative polycythemia vera.
Röthlisberger B; Huber A; Bargetzi M; Mendez A; Heizmann M
Leuk Lymphoma; 2008 Mar; 49(3):586-8. PubMed ID: 18297539
[No Abstract] [Full Text] [Related]
14. Detection of a new JAK2 D620E mutation in addition to V617F in a patient with polycythemia vera.
Grünebach F; Bross-Bach U; Kanz L; Brossart P
Leukemia; 2006 Dec; 20(12):2210-1. PubMed ID: 17008888
[No Abstract] [Full Text] [Related]
15. A Clue in JAK2: Masked Polycythemia Vera.
Rosenstein BE; Ives ST; Wiernik A
Am J Med; 2016 Oct; 129(10):1051-3. PubMed ID: 27427321
[No Abstract] [Full Text] [Related]
16. JAK2 Mutations are present in all cases of polycythemia vera.
Wang YL; Vandris K; Jones A; Cross NC; Christos P; Adriano F; Silver RT
Leukemia; 2008 Jun; 22(6):1289. PubMed ID: 18079740
[No Abstract] [Full Text] [Related]
17. De novo polycythaemia vera arising 5 years following acute myeloid leukemia remission: suggestion of a chemotherapy resistant JAK2 clone.
Portell CA; Sekeres MA; Rogers HJ; Tiu RV
Br J Haematol; 2012 Apr; 157(2):266-7. PubMed ID: 22150289
[No Abstract] [Full Text] [Related]
18. The treatment of polycythaemia vera: an update in the JAK2 era.
Finazzi G; Barbui T
Intern Emerg Med; 2007 Mar; 2(1):13-8. PubMed ID: 17551678
[TBL] [Abstract][Full Text] [Related]
19. No evidence for JAK2(V617F) mutation in monoclonal B cells in 2 patients with polycythaemia vera and concurrent monoclonal B cell disorder.
Stijnis C; Kroes WG; Balkassmi S; Marijt EW; van Rossum AP; Bakker E; Vlasveld LT
Acta Haematol; 2012; 128(3):183-6. PubMed ID: 22890406
[TBL] [Abstract][Full Text] [Related]
20. A resequencing program in India detects the rare JAK2 L579F mutation in patients suffering from polycythemia vera and negative for JAK2 V617F.
Acharya A; Vaniawala S; Parekh H; Sheikh H; Patel H; Ali R; Khan A; Nagee A; Kunjadia P; Mukhopadhyaya PN
Int J Lab Hematol; 2014 Aug; 36(4):e30-3. PubMed ID: 24033912
[No Abstract] [Full Text] [Related]
[Next] [New Search]
